Akero Therapeutics, Inc. (AKRO)

Market Cap	2.55B
Revenue (ttm)	n/a
Net Income (ttm)	-115.52M
Shares Out	55.60M
EPS (ttm)	-2.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,913
Open	45.37
Previous Close	45.92
Day's Range	45.01 - 45.90
52-Week Range	25.97 - 58.38
Beta	-0.93
Analysts	Strong Buy
Price Target	63.38 (+38.2%)
Earnings Date	Nov 3, 2023

About AKRO

Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatmen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 20, 2019
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: AKRO

Analyst Forecast

According to 8 analysts, the average rating for AKRO stock is "Strong Buy." The 12-month stock price forecast is $63.38, which is an increase of 38.20% from the latest price.

Price Target

$63.38

(38.20% upside)

Analyst Consensus: Strong Buy